La catena delle opzioni mostra i dati chiave delle opzioni azionarie di Clene a vari prezzi di esercizio e date di scadenza. I trader utilizzano queste informazioni per analizzare potenziali operazioni e valutare il sentiment del mercato per Clene..

Clene (NASDAQ:CLNNW) Azioni, Catena delle Opzioni

Clene Inc is a clinical-stage pharmaceutical company pioneering the discovery, development, and commercialization of novel clean-surfaced nanotechnology (CSN) therapeutics. It is focused on the development of therapeutics for neurodegenerative diseases. It developed an electro-crystal-chemistry drug development platform that enables the production of concentrated, stable, clean-surfaced nanocrystal suspensions. It operates in one segment the development and commercialization of dietary supplements (Supplements).

Clene Inc

BMO Capital analyst Michael Zaremski maintains Arch Capital Group (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/ACGL#NASDAQ">ACGL</a>) with a Market Perform and raises the price target from $98 to $104.

News

Price Target

Analyst Ratings

ACGL

BMO Capital Maintains Market Perform on Arch Capital Group, Raises Price Target to $104

RBC Capital analyst Maurice Choy maintains TransAlta (TSX:<a class="ticker" href="https://www.benzinga.com/stock/TA#TSX">TA</a>) with a Outperform and raises the price target from C$14 to C$16.

TSX:TA

RBC Capital Maintains Outperform on TransAlta, Raises Price Target to C$16

Bitcoin&nbsp;(CRYPTO:&nbsp;<a href="https://www.benzinga.com/quote/btc/usd">BTC</a>) mining stocks&nbsp;MARA Holdings&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MARA#NASDAQ">MARA</a>),&nbsp;Riot Platforms&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RIOT#NASDAQ">RIOT</a>)&nbsp;and&nbsp;CleanSpark&nbsp;Inc&nbsp;(NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/CLSK#NASDAQ">CLSK</a>) are surging Wednesday morning after Donald Trump was elected as the <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">next president of the United States</a>.
What To Know: Broader markets are ripping higher in early trading Wednesday after Trump secured a second term as investors expect U.S.-focused companies to benefit from potential lower taxes and tariffs.
Crypto markets appear to be among the biggest immediate beneficiaries with Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) hitting new all-time highs above $75,000 and several other popular cryptocurrencies surging on the election results. Trump has positioned himself as a pro-crypto candidate.
Bitcoin mining stocks are outpacing gains in underlying cryptocurrencies in early trading Wednesday. Trump said earlier this year that he wanted all Bitcoin <a href="https://www.benzinga.com/markets/cryptocurrency/24/06/39289772/donald-trump-wants-all-the-remaining-bitcoin-to-be-made-in-the-usa">to be made in the U.S.</a>
Check This Out: <a href="https://www.benzinga.com/markets/cryptocurrency/24/11/41770352/bitcoins-future-under-president-elect-donald-trump-a-look-at-his-crypto-policies">Bitcoin&#8217;s Future Under President-Elect Donald Trump: A Look At His Crypto Policies</a>
MARA Holdings, Riot and CleanSpark all released&nbsp;<a href="https://www.benzinga.com/pressreleases/24/11/n41714046/cleanspark-releases-october-2024-bitcoin-mining-update">mining updates for October</a> at the beginning of the week. Here&#8217;s a look at how the miners stack up against each other.
<ul>
<li>MARA Holdings mined 717 bitcoin in October, up 2% month-over-month. The company said it held a total of 27,562 bitcoin as of Oct. 31.</li>
</ul>
<ul>
<li>Riot mined 505 bitcoin in October, up 23% month-over-month. The company said it held 10,928 bitcoin as of the end of the month.</li>
</ul>
<ul>
<li>CleanSpark mined 655 bitcoin in October, up 32% on a month-over-month basis. The company had total bitcoin holdings of 8,701 as of Oct. 31.</li>
</ul>
Bitcoin was up about 7% over a 24-hour period, trading around $74,640 at the time of publication, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
MARA, RIOT, CLSK: At publication time, MARA shares were up 9.21% at $17.73, Riot shares were up 12.3% at $10.90 and CleanSpark shares were up 11.6% at $11.74, according to <a href="http://pro.benzinga.com">Benzinga Pro</a>.
Photo: Shutterstock.

Coverage of Bitcoin, Etherum, Ripple and all the latest digital currencies.

Cryptocurrency

Movers

$BTC

CLSK

MARA

RIOT

Bitcoin Mining Stocks MARA Holdings, Riot Platforms And CleanSpark Are Charging Higher Wednesday: What's Going On?

Wells Fargo analyst Michael Sison maintains DuPont de Nemours (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DD#NYSE">DD</a>) with a Overweight and raises the price target from $105 to $107.

Wells Fargo Maintains Overweight on DuPont de Nemours, Raises Price Target to $107

Wells Fargo analyst Joseph O'Dea maintains Emerson Electric (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/EMR#NYSE">EMR</a>) with a Overweight and raises the price target from $128 to $135.

Wells Fargo Maintains Overweight on Emerson Electric, Raises Price Target to $135

Movie theater company AMC Entertainment Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMC#NYSE">AMC</a>) could highlight market share gains and a strong box office performance when the company reports third-quarter financial results Wednesday<a href="https://www.benzinga.com/earnings"> after the market close.</a>
AMC Earnings Estimates: Analysts expect AMC to report third-quarter revenue of $1.33 billion, down from $1.41 billion in last year's third quarter, according to data <a href="https://www.benzinga.com/pro/?utm_source=BZprocontent110624&amp;t=be2bearmibe3na1">from Benzinga Pro.</a>
The company has beaten revenue estimates from analysts in nine of the last 10 quarters, missing in the most recently reported second quarter.
Analysts expect the company to report a loss of 11 cents per share, compared to a loss of 9 cents per share in last year's third quarter. The company has beaten analyst estimates for earnings per share in seven of the last eight quarters, meeting expectations in the most recently reported second quarter.
Read Also: <a href="https://www.benzinga.com/general/entertainment/24/09/41073813/amc-survival-against-challenging-sector-brings-magic-comparison-harry-houdini-works-at-amc">AMC Survival Against Challenging Sector Brings Magic Comparison: &#8216;Harry Houdini Works At AMC&#8217;</a>
What AMC Analysts Are Saying: Wedbush analyst Alicia Reese <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40165453/amc-stock-to-remain-volatile-after-q2-results-analysts-praise-market-share-gains-ca">detailed the company's</a> potential market share gains in an investor note after second-quarter financial results.
The analyst, who has a Neutral rating and a $4 price target, said the company needs to reduce its high debt load to help with future growth.
"AMC can also drive revenue growth in Europe with theater upgrades. However, it is unlikely to do so until it works through balance sheet right-sizing," Reese said.
The analyst said a large network of premium screens and concert movie distribution deals could help "justify its premium valuation," but cautioned on more potential capital needed to cover interest payments.
&#8220;We expect AMC&#8217;s shares to remain volatile as its shareholders dislike its frequent share issuances.&#8221;
Benchmark analyst Mike Hickey said AMC's second quarter saw a strong performance with several box office hits.
The analyst, who has a Market Weight rating and no price target, said the concession revenue per attendee was up in the second quarter for domestic theaters along with higher average ticket prices, positives for the company.
Key Items to Watch From AMC: The third-quarter box office rose 0.6% year-over-year domestically according to <a href="https://www.boxofficemojo.com/quarter/q3/?grossesOption=calendarGrosses">data </a>from BoxOfficeMojo. The quarter saw hit films like "Deadpool &amp; Wolverine," "Despicable Me 4," "Twisters" and "Beetlejuice Beetlejuice" released.
AMC's quarterly report comes after peer Cinemark Holdings (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CNK#NYSE">CNK</a>) <a href="https://www.benzinga.com/news/earnings/24/10/41660851/whats-going-on-with-cinemark-holdings-stock-thursday">reported quarterly earnings </a>that saw earnings per share and revenue both beat analyst estimates. The company&#8217;s shares rose after the report, and analysts raised<a href="https://www.benzinga.com/quote/CNK/analyst-ratings"> their price targets.</a>
Cinemark said the third quarter box office exceeded expectations and was the highest quarterly total since the COVID-19 pandemic.
A similar report from AMC could go a long way toward showing a box office recovery and growth ahead.
Fourth-quarter domestic box office hasn't been as strong, with "Venom: The Last Dance" the current top film of the quarter at $92.0 million. Upcoming movies like "Gladiator II," "Moana 2," "Wicked," "Sonic the Hedgehog 3" and "Mufasa: The Lion King" could bring optimism for a strong end to the year for movie theater companies.
AMC CEO Adam Aron has been more optimistic about upcoming years than 2024, which could be echoed in his commentary on Wednesday.
&#8220;With a long list of blockbuster movie titles opening in theaters during the remainder of the year and into 2025 and 2026, the industry-wide box office now appears to us to be poised for sustained growth. Looking ahead, we believe that bodes ever so well for the increasing cash generation potential from AMC&#8217;s movie theaters both at home and abroad," Aron said earlier this year.
AMC Price Action: AMC stock was up 2.3% to $4.50 on Wednesday versus a 52-week trading range of $2.38 to $11.88. AMC stock is down 28% year-to-date in 2024.
Read Next: 
<ul>
<li><a href="https://www.benzinga.com/general/entertainment/24/05/39010959/amc-ceo-says-were-still-here-how-taylor-swift-popcorn-buckets-help-movie-theater-from-going">AMC CEO Says &#8216;We&#8217;re Still Here&#8217;: How Taylor Swift, Popcorn Buckets Help Movie Theater From Going &#8216;Kaplooey&#8217;</a></li>
</ul>
Photo: Shutterstock

Entertainment

Previews

Trading Ideas

AMC Q3 Earnings Preview: Can 'Deadpool & Wolverine' Box Office Strength Lift Stock?

Wells Fargo analyst Jason Haas maintains UL Solutions (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/ULS#NYSE">ULS</a>) with a Overweight and raises the price target from $56 to $62.

Wells Fargo Maintains Overweight on UL Solutions, Raises Price Target to $62

<a href="https://thebearcave.substack.com/p/problems-at-viasat-vsat" title="https://thebearcave.substack.com/p/problems-at-viasat-vsat">https://thebearcave.substack.com/p/problems-at-viasat-vsat</a>

VSAT

Watching Viasat; The Bear Cave Newsletter Issues Report Titled 'Problems at Viasat (VSAT)'

Susquehanna analyst Christopher Rolland maintains NXP Semiconductors (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NXPI#NASDAQ">NXPI</a>) with a Neutral and lowers the price target from $260 to $250.

NXPI

Susquehanna Maintains Neutral on NXP Semiconductors, Lowers Price Target to $250

Wells Fargo analyst Jason Haas maintains Gartner (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IT#NYSE">IT</a>) with a Underweight and raises the price target from $460 to $470.

Wells Fargo Maintains Underweight on Gartner, Raises Price Target to $470

Susquehanna analyst Christopher Rolland maintains Microchip Technology (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MCHP#NASDAQ">MCHP</a>) with a Positive and lowers the price target from $95 to $90.

MCHP

Susquehanna Maintains Positive on Microchip Technology, Lowers Price Target to $90

Financial giants have made a conspicuous bearish move on Freeport-McMoRan. Our analysis of options history for Freeport-McMoRan (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FCX#NYSE">FCX</a>) revealed 16 unusual trades.
Delving into the details, we found 31% of traders were bullish, while 56% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $57,912, and 14 were calls, valued at $1,995,172.
<h3>Predicted Price Range</h3>
After evaluating the trading volumes and Open Interest, it's evident that the major market movers are focusing on a price band between $33.0 and $50.0 for Freeport-McMoRan, spanning the last three months.
<h3>Volume &amp; Open Interest Development</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Freeport-McMoRan's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Freeport-McMoRan's whale activity within a strike price range from $33.0 to $50.0 in the last 30 days. 
<h3>Freeport-McMoRan Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907075_0.png" alt="Options Call Chart" />
<h3>Biggest Options Spotted:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.6</td>
<td>$1.55</td>
<td>$1.55</td>
<td>$50.00</td>
<td>$520.3K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.43</td>
<td>$1.5</td>
<td>$50.00</td>
<td>$506.2K</td>
<td>35.4K</td>
<td>10.7K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$1.54</td>
<td>$1.51</td>
<td>$1.51</td>
<td>$50.00</td>
<td>$204.1K</td>
<td>35.4K</td>
<td>5.1K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$1.49</td>
<td>$1.48</td>
<td>$1.49</td>
<td>$50.00</td>
<td>$139.3K</td>
<td>35.4K</td>
<td>7.4K</td>
</tr>
<tr>
<td>FCX</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/17/25</td>
<td>$1.45</td>
<td>$1.43</td>
<td>$1.43</td>
<td>$50.00</td>
<td>$98.6K</td>
<td>35.4K</td>
<td>6.4K</td>
</tr>
</tbody>
</table>

<h3>About Freeport-McMoRan</h3>
Freeport-McMoRan Inc is an international mining company. It has organized its mining operations into four primary divisions: North America copper mines, South America mining, Indonesia mining and Molybdenum mines. Its reportable segments include the Morenci, Cerro Verde and Grasberg (Indonesia mining) copper mines, the Rod &amp; Refining operations and Atlantic Copper Smelting and Refining. It derives key revenue from the sale of Copper.
After a thorough review of the options trading surrounding Freeport-McMoRan, we move to examine the company in more detail. This includes an assessment of its current market status and performance.
<h3>Freeport-McMoRan's Current Market Status</h3>
<ul>
<li>With a volume of 3,545,458, the price of FCX is down -2.09% at $46.01. </li>
<li>RSI indicators hint that the underlying stock may be approaching oversold.</li>
<li>Next earnings are expected to be released in 77 days.</li>
</ul>
<h3>Professional Analyst Ratings for Freeport-McMoRan</h3>
4 market experts have recently issued ratings for this stock, with a consensus target price of $54.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Raymond James keeps a Outperform rating on Freeport-McMoRan with a target price of $57. 
&#x2A; An analyst from Scotiabank has decided to maintain their Sector Perform rating on Freeport-McMoRan, which currently sits at a price target of $53. 
&#x2A; Maintaining their stance, an analyst from Scotiabank continues to hold a Sector Perform rating for Freeport-McMoRan, targeting a price of $52. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Neutral rating for Freeport-McMoRan, targeting a price of $55. 
Options are a riskier asset compared to just trading the stock, but they have higher profit potential. Serious options traders manage this risk by educating themselves daily, scaling in and out of trades, following more than one indicator, and following the markets closely.
If you want to stay updated on the latest options trades for Freeport-McMoRan, <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> gives you real-time options trades alerts.

Options

Markets

This Is What Whales Are Betting On Freeport-McMoRan

Financial giants have made a conspicuous bullish move on Mastercard. Our analysis of options history for Mastercard (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/MA#NYSE">MA</a>) revealed 9 unusual trades.
Delving into the details, we found 33% of traders were bullish, while 33% showed bearish tendencies. Out of all the trades we spotted, 2 were puts, with a value of $98,538, and 7 were calls, valued at $507,653.
<h3>Expected Price Movements</h3>
Analyzing the Volume and Open Interest in these contracts, it seems that the big players have been eyeing a price window from $390.0 to $530.0 for Mastercard during the past quarter. 
<h3>Insights into Volume &amp; Open Interest</h3>
In today's trading context, the average open interest for options of Mastercard stands at 232.62, with a total volume reaching 226.00. The accompanying chart delineates the progression of both call and put option volume and open interest for high-value trades in Mastercard, situated within the strike price corridor from $390.0 to $530.0, throughout the last 30 days.
<h3>Mastercard Option Activity Analysis: Last 30 Days</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907070_0.png" alt="Options Call Chart" />
<h3>Largest Options Trades Observed:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th style="text-align: right;">Open Interest</th>
<th style="text-align: right;">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$124.65</td>
<td>$121.65</td>
<td>$123.99</td>
<td>$400.00</td>
<td>$99.1K</td>
<td style="text-align: right;">487</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$133.4</td>
<td>$129.0</td>
<td>$129.0</td>
<td>$420.00</td>
<td>$90.4K</td>
<td style="text-align: right;">183</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/16/26</td>
<td>$155.85</td>
<td>$153.5</td>
<td>$153.55</td>
<td>$390.00</td>
<td>$76.7K</td>
<td style="text-align: right;">33</td>
<td style="text-align: right;">12</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>01/16/26</td>
<td>$150.35</td>
<td>$145.25</td>
<td>$145.25</td>
<td>$400.00</td>
<td>$72.6K</td>
<td style="text-align: right;">198</td>
<td style="text-align: right;">7</td>
</tr>
<tr>
<td>MA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$7.05</td>
<td>$6.9</td>
<td>$7.05</td>
<td>$520.00</td>
<td>$70.6K</td>
<td style="text-align: right;">801</td>
<td style="text-align: right;">98</td>
</tr>
</tbody>
</table>

<h3>About Mastercard</h3>
Mastercard is the second-largest payment processor in the world, having processed close to over $9 trillion in volume during 2023. Mastercard operates in over 200 countries and processes transactions in over 150 currencies.
<h3>Current Position of Mastercard</h3>
<ul>
<li>With a volume of 778,613, the price of MA is up 2.7% at $519.19. </li>
<li>RSI indicators hint that the underlying stock may be approaching overbought.</li>
<li>Next earnings are expected to be released in 84 days.</li>
</ul>
<h3>Professional Analyst Ratings for Mastercard</h3>
Over the past month, 5 industry analysts have shared their insights on this stock, proposing an average target price of $565.2.
Unusual Options Activity Detected: Smart Money on the Move
Benzinga Edge's Unusual Options board spots potential market movers before they happen. See what positions big money is taking on your favorite stocks. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=Be8be9arja3be22bz20&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; Consistent in their evaluation, an analyst from Macquarie keeps a Outperform rating on Mastercard with a target price of $565. 
&#x2A; An analyst from Keybanc persists with their Overweight rating on Mastercard, maintaining a target price of $580. 
&#x2A; An analyst from Morgan Stanley persists with their Overweight rating on Mastercard, maintaining a target price of $544. 
&#x2A; Maintaining their stance, an analyst from Susquehanna continues to hold a Positive rating for Mastercard, targeting a price of $605. 
&#x2A; Maintaining their stance, an analyst from Mizuho continues to hold a Outperform rating for Mastercard, targeting a price of $532. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Mastercard with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

Mastercard Options Trading: A Deep Dive into Market Sentiment

Investors with a lot of money to spend have taken a bearish stance on Moderna (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRNA#NASDAQ">MRNA</a>).
And retail traders should know.
We noticed this today when the trades showed up on publicly available options history that we track here at Benzinga.
Whether these are institutions or just wealthy individuals, we don't know. But when something this big happens with MRNA, it often means somebody knows something is about to happen.
So how do we know what these investors just did? 
Today, <a href="https://pro.benzinga.com/?utm_source=insights">Benzinga</a>'s options scanner spotted 11 uncommon options trades for Moderna.
This isn't normal.
The overall sentiment of these big-money traders is split between 36% bullish and 54%, bearish.
Out of all of the special options we uncovered, 4 are puts, for a total amount of $214,735, and 7 are calls, for a total amount of $478,040.
<h3>Projected Price Targets</h3>
Based on the trading activity, it appears that the significant investors are aiming for a price territory stretching from $40.0 to $130.0 for Moderna over the recent three months. 
<h3>Analyzing Volume &amp; Open Interest</h3>
Looking at the volume and open interest is an insightful way to conduct due diligence on a stock.
This data can help you track the liquidity and interest for Moderna's options for a given strike price.
Below, we can observe the evolution of the volume and open interest of calls and puts, respectively, for all of Moderna's whale activity within a strike price range from $40.0 to $130.0 in the last 30 days. 
<h3>Moderna Call and Put Volume: 30-Day Overview</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907065_0.png" alt="Options Call Chart" />
<h3>Significant Options Trades Detected:</h3>

<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Ask</th>
<th>Bid</th>
<th>Price</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th>Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$1.31</td>
<td>$1.27</td>
<td>$1.31</td>
<td>$60.00</td>
<td>$107.5K</td>
<td>2.9K</td>
<td>1.6K</td>
</tr>
<tr>
<td>MRNA</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>11/15/24</td>
<td>$3.55</td>
<td>$3.35</td>
<td>$3.35</td>
<td>$50.00</td>
<td>$105.8K</td>
<td>4.7K</td>
<td>513</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$16.7</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$88.2K</td>
<td>40</td>
<td>150</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.0</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$78.2K</td>
<td>40</td>
<td>97</td>
</tr>
<tr>
<td>MRNA</td>
<td>CALL</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>04/17/25</td>
<td>$17.4</td>
<td>$16.65</td>
<td>$16.65</td>
<td>$40.00</td>
<td>$73.2K</td>
<td>40</td>
<td>50</td>
</tr>
</tbody>
</table>

<h3>About Moderna</h3>
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its covid vaccine, which was authorized in the United States in December 2020. Moderna had 40 mRNA development candidates in clinical development as of September 2024. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
<h3>Where Is Moderna Standing Right Now?</h3>
<ul>
<li>Trading volume stands at 3,021,467, with MRNA's price down by -1.31%, positioned at $52.59.</li>
<li>RSI indicators show the stock to be may be oversold.</li>
<li>Earnings announcement expected in 1 days.</li>
</ul>
<h3>Professional Analyst Ratings for Moderna</h3>
A total of 4 professional analysts have given their take on this stock in the last 30 days, setting an average price target of $69.25.
Turn $1000 into $1270 in just 20 days?
20-year pro options trader reveals his one-line chart technique that shows when to buy and sell. Copy his trades, which have had averaged a 27% profit every 20 days. <a href="https://www.benzinga.com/premium/ideas/options-moneyline-2/?t=Moop1arja3be22op14&amp;utm_source=benzinga-insights">Click here for access</a>. 
&#x2A; An analyst from Bernstein has revised its rating downward to Market Perform, adjusting the price target to $55. 
&#x2A; An analyst from UBS persists with their Buy rating on Moderna, maintaining a target price of $108. 
&#x2A; Maintaining their stance, an analyst from JP Morgan continues to hold a Underweight rating for Moderna, targeting a price of $59. 
&#x2A; Consistent in their evaluation, an analyst from Jefferies keeps a Hold rating on Moderna with a target price of $55. 
Trading options involves greater risks but also offers the potential for higher profits. Savvy traders mitigate these risks through ongoing education, strategic trade adjustments, utilizing various indicators, and staying attuned to market dynamics. Keep up with the latest options trades for Moderna with <a href="https://benzinga.grsm.io/register174">Benzinga Pro</a> for real-time alerts.

MRNA

Moderna Options Trading: A Deep Dive into Market Sentiment

<a href="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html" title="https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html">https://www.cnbc.com/2024/11/06/planet-fitness-bid-for-bankrupt-blink-fitness.html</a>

PLNT

'Planet Fitness wants to acquire bankrupt budget-fitness chain Blink Holdings' - CNBC

Macro Economic Events

Econ #s

Economics

USA Gasoline Inventories 0.412M Barrel Build Vs 1.650M Barrel Draw Est.; 2.707M Barrel Draw Prior

EIA Weekly Distillates Stocks 2.947M Barrel Build Vs 1.500M Barrel Draw Est.; 0.977M Barrel Draw Prior

Iron Mountain (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IRM#NYSE">IRM</a>) has outperformed the market over the past 5 years by 15.97% on an annualized basis producing an average annual return of 29.67%. Currently, Iron Mountain has a market capitalization of $37.08 billion. 
Buying $100 In IRM: If an investor had bought $100 of IRM stock 5 years ago, it would be worth $364.41 today based on a price of $126.40 for IRM at the time of writing.
<h3>Iron Mountain's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907021_0_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

$100 Invested In Iron Mountain 5 Years Ago Would Be Worth This Much Today

Williams Companies (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/WMB#NYSE">WMB</a>) has outperformed the market over the past 5 years by 6.16% on an annualized basis producing an average annual return of 19.86%. Currently, Williams Companies has a market capitalization of $66.91 billion. 
Buying $1000 In WMB: If an investor had bought $1000 of WMB stock 5 years ago, it would be worth $2,469.20 today based on a price of $53.05 for WMB at the time of writing.
<h3>Williams Companies's Performance Over Last 5 Years</h3>
<img src="https://www.benzinga.com/files/images/story/2024/1730907016_0.png" alt="comp_fig" />
Finally -- what's the point of all this? The key insight to take from this article is to note how much of a difference compounded returns can make in your cash growth over a period of time.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

If You Invested $1000 In This Stock 5 Years Ago, You Would Have $2,500 Today

Wells Fargo analyst Brandon Couillard maintains Bruker (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/BRKR#NASDAQ">BRKR</a>) with a Overweight and lowers the price target from $78 to $75.

BRKR

Wells Fargo Maintains Overweight on Bruker, Lowers Price Target to $75

AbbVie

Alnylam Pharmaceuticals, Inc. - Common Stock

Alnylam Pharmaceuticals

Amgen

argenx

BeiGene, Ltd. - American Depositary Shares

BeiGene

Biogen

BioMarin Pharmaceutical Inc. - Common Stock

Biomarin Pharmaceutical

BioNTech

Clene

Exact Sciences Corporation - Common Stock

Exact Sciences

Exelixis

Gilead Sciences

Genmab

Incyte

Insmed

Legend Biotech Corporation - American Depositary Shares

Legend Biotech

Moderna

Neurocrine Biosciences, Inc. - Common Stock

Neurocrine Biosciences

Natera

Vaxcyte

Regeneron Pharmaceuticals, Inc. - Common Stock

Regeneron Pharmaceuticals

Roivant Sciences

Revolution Medicines, Inc. - Common Stock

Revolution Medicines

Summit Therapeutics

Sarepta Therapeutics, Inc. - Common Stock

Sarepta Therapeutics

United Therapeutics Corporation - Common Stock

United Therapeutics

Vertex Pharmaceuticals Incorporated - Common Stock

Comments

Clene

Clene (CLNNW) Opzioni

No option chain data available. Please try again later

Notizie

PARTNER/COLLABORATORE

BENZINGA NEL MONDO